AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising Alzheimer’s treatment, ALIA-1758, and the biotech’s innovative Modular Delivery (MODEL) platform, which could overcome significant barriers in treating neurological disorders, particularly Alzheimer’s disease. Key Drivers Behind the Acquisition AbbVie aims […]
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. The funds are aimed at accelerating the pivotal Phase 2b/3 trial for its promising Alzheimer’s treatment, Xanamem. This decisive move aims to fast-track patient enrolment and bring the potential breakthrough […]
Athira Pharma’s stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for its experimental Alzheimer’s drug, fosgonimeton, failed to meet primary and key secondary endpoints. This significant drop reflects investor concern over the future of the company’s approach to treating neurodegenerative diseases, particularly Alzheimer’s. The trial aimed to demonstrate […]
Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD clinical trial. This trial is pivotal in evaluating fosgonimeton, a novel treatment for individuals with mild-to-moderate Alzheimer’s disease (AD). Athira is set to unveil topline results by the end of […]
In a significant stride towards addressing early Alzheimer’s disease, AriBio Co., Ltd. (AriBio) has announced an exclusive agreement to market AR1001, a pioneering investigational drug, in China. The deal, potentially worth up to $770 million USD, marks a critical milestone in the global fight against Alzheimer’s disease, particularly targeting the growing patient population in China. […]
In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer’s disease, has secured an investment of up to $15 million from Eisai Inc., a globally recognized human health care company. This strategic partnership underscores a shared commitment between the two firms to […]
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a pioneering biopharmaceutical company in the development of novel treatments for neurodegenerative diseases, has recently taken a significant step forward in the fight against Alzheimer’s disease. The company announced the filing of a new composition-of-matter patent for ALPHA-1062, its leading drug candidate designed to treat mild-to-moderate Alzheimer’s Disease, […]
In a significant development for the life sciences sector, Schroders Capital Global Innovation Trust plc has announced a strategic investment of $1.6 million (£1.3 million) in Neurona Therapeutics, a leading US-based clinical-stage cell therapy company. This investment was part of Neurona’s Series E financing round, which successfully raised $120 million. The round was co-led by […]
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected to drive growth in both the near and long term. The company is set to continue advancing LEQEMBI (lecanemab-irmb), the first anti-amyloid beta treatment with FDA traditional approval in the […]
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme’s ENHANZE drug delivery technology to potentially transform the administration of Acumen’s Alzheimer’s treatment. Groundbreaking Approach to Alzheimer’s Treatment Administration The agreement details include an initial payment by Acumen to Halozyme, alongside the possibility […]
